Jens Thorvald Rosenberg1,2, Joshua M. Kogot3, Chris Ridel3, Geoffery F. Strouse3, Samuel C. Grant1,2
1The National High Magnetic Field Laboratory, Tallahassee, FL, USA; 2Chemical and Biomedical Engineering, Florida State University, Tallahassee, FL, USA; 3Chemistry and Biochemistry, Florida State University, Tallahassee, FL, USA
We have assessed murine microglia cells (Bv-2) and human teratocarcinoma cells (NT2) for future use with a novel bimodal MR contrast agent. These cells can be used to identify regions of neurodegeneration. To evaluate contrast enhancement, we have compared the performance of our bimodal agents consisting of Dy-label quantum dots to SPIOs and Dy chelates (DOTA and DTPA).